Nephrocheck (Astute Medical, San Diego, CA, USA), containing tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7), has been accepted as the first diagnostic test for AKI approved by the US Food and Drug Administration (24). The gene discussed is TIMP2; the disease is acute kidney injury.